Modeling and simulation is proposed to support drug development phase transitions in oncology. Longitudinal tumor-size data recorded in patients are modeled to inform treatment efficacy, and the tumor growth inhibition (TGI) metrics are related to clinical end points, e.g., overall survival.
2014 年 08 月 1 日
Author(s): Laurent Claret, Rene Bruno
Year: 2014 年 08 月 1 日